Dahut W - Search Results

1

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.

Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Peer CJ, et al. Among authors: dahut w. Clin Cancer Res. 2012 Apr 1;18(7):2099-107. doi: 10.1158/1078-0432.CCR-11-2484. Epub 2012 Feb 3. Clin Cancer Res. 2012. PMID: 22307138 Free PMC article.

2

Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples.

Geoffroy F, Dahut W, Takimoto CH, Grem JL. Geoffroy F, et al. Among authors: dahut w. Clin Cancer Res. 1995 Nov;1(11):1345-51. Clin Cancer Res. 1995. PMID: 9815930 Clinical Trial.

3

Taxanes in hormone-refractory prostate cancer.

Kang MH, Figg WD, Dahut W. Kang MH, et al. Among authors: dahut w. Cancer Pract. 1999 Sep-Oct;7(5):270-2. doi: 10.1046/j.1523-5394.1999.75005.x. Cancer Pract. 1999. PMID: 10687598 Review. No abstract available.

4

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. Among authors: dahut w. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

5

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Among authors: dahut w. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

6

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: dahut w. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

7

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E. Figg WD, et al. Among authors: dahut w. Clin Cancer Res. 2001 Jul;7(7):1888-93. Clin Cancer Res. 2001. PMID: 11448901 Clinical Trial.

8

Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.

Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W. Carrasquillo JA, et al. Among authors: dahut w. J Nucl Med. 2001 Sep;42(9):1359-63. J Nucl Med. 2001. PMID: 11535725 Free article.

9

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Among authors: dahut wl. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

10

Leptomeningeal carcinomatosis in metastatic prostate cancer.

Neelapu S, Figg WD, Dahut W, Reed E. Neelapu S, et al. Among authors: dahut w. South Med J. 2002 Jan;95(1):107-8. doi: 10.1097/00007611-200201000-00022. South Med J. 2002. PMID: 11827241 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page